Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer

Yoshinobu Maeda, Yoshihiko Segawa, Nagio Takigawa, Ichiro Takata, Nobukazu Fujimoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Serum soluble cytokeratin 19 fragment (CYFRA) levels were measured in 251 patients with lung cancer and 139 patients with benign lung diseases to determine the clinical usefulness of CYFRA level determination in the diagnosis and monitoring of lung cancer. Serum levels of CYFRA were measured by a 2-step sandwich ELISA method. When the cut-off value was defined as 3.5 ng/ml, which was associated with a specificity of 95% for benign lung diseases, CYFRA had a high sensitivity (53%) in all patients with lung cancer. Both the serum level of CYFRA and its sensitivity increased significantly with the increase in clinical stage. A comparison of areas under receiver operating characteristic curves showed that CYFRA had the most power of discrimination in the diagnosis of lung cancer among markers including carcinoembryonic antigen, squamous cell carcinoma antigen, carbohydrate antigen 19-9, and neuron-specific enolase. A good correlation was found between serial changes in serum CYFRA levels during therapy and clinical responses for 18 patients who underwent chemotherapy and/or radiotherapy. Our findings suggest that CYFRA may be a marker of choice for screening and monitoring of lung cancer, particularly squamous cell carcinoma.

Original languageEnglish
Pages (from-to)764-771
Number of pages8
JournalInternal Medicine
Volume35
Issue number10
Publication statusPublished - Oct 1996
Externally publishedYes

Fingerprint

Keratin-19
Tumor Biomarkers
Lung Neoplasms
Serum
Lung Diseases
Phosphopyruvate Hydratase
Carcinoembryonic Antigen
ROC Curve
Squamous Cell Carcinoma
Radiotherapy
Enzyme-Linked Immunosorbent Assay
Carbohydrates
Antigens
Drug Therapy

Keywords

  • Carbohydrate antigen 19-9
  • Carcinoembryonic antigen
  • Neuron-specific enolase
  • Non-small cell lung cancer
  • Squamous cell carcinoma
  • Squamous cell carcinoma antigen

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Maeda, Y., Segawa, Y., Takigawa, N., Takata, I., & Fujimoto, N. (1996). Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. Internal Medicine, 35(10), 764-771.

Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. / Maeda, Yoshinobu; Segawa, Yoshihiko; Takigawa, Nagio; Takata, Ichiro; Fujimoto, Nobukazu.

In: Internal Medicine, Vol. 35, No. 10, 10.1996, p. 764-771.

Research output: Contribution to journalArticle

Maeda, Y, Segawa, Y, Takigawa, N, Takata, I & Fujimoto, N 1996, 'Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer', Internal Medicine, vol. 35, no. 10, pp. 764-771.
Maeda Y, Segawa Y, Takigawa N, Takata I, Fujimoto N. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. Internal Medicine. 1996 Oct;35(10):764-771.
Maeda, Yoshinobu ; Segawa, Yoshihiko ; Takigawa, Nagio ; Takata, Ichiro ; Fujimoto, Nobukazu. / Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. In: Internal Medicine. 1996 ; Vol. 35, No. 10. pp. 764-771.
@article{337f2cdddf6c41e3862415791406418c,
title = "Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer",
abstract = "Serum soluble cytokeratin 19 fragment (CYFRA) levels were measured in 251 patients with lung cancer and 139 patients with benign lung diseases to determine the clinical usefulness of CYFRA level determination in the diagnosis and monitoring of lung cancer. Serum levels of CYFRA were measured by a 2-step sandwich ELISA method. When the cut-off value was defined as 3.5 ng/ml, which was associated with a specificity of 95{\%} for benign lung diseases, CYFRA had a high sensitivity (53{\%}) in all patients with lung cancer. Both the serum level of CYFRA and its sensitivity increased significantly with the increase in clinical stage. A comparison of areas under receiver operating characteristic curves showed that CYFRA had the most power of discrimination in the diagnosis of lung cancer among markers including carcinoembryonic antigen, squamous cell carcinoma antigen, carbohydrate antigen 19-9, and neuron-specific enolase. A good correlation was found between serial changes in serum CYFRA levels during therapy and clinical responses for 18 patients who underwent chemotherapy and/or radiotherapy. Our findings suggest that CYFRA may be a marker of choice for screening and monitoring of lung cancer, particularly squamous cell carcinoma.",
keywords = "Carbohydrate antigen 19-9, Carcinoembryonic antigen, Neuron-specific enolase, Non-small cell lung cancer, Squamous cell carcinoma, Squamous cell carcinoma antigen",
author = "Yoshinobu Maeda and Yoshihiko Segawa and Nagio Takigawa and Ichiro Takata and Nobukazu Fujimoto",
year = "1996",
month = "10",
language = "English",
volume = "35",
pages = "764--771",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "10",

}

TY - JOUR

T1 - Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer

AU - Maeda, Yoshinobu

AU - Segawa, Yoshihiko

AU - Takigawa, Nagio

AU - Takata, Ichiro

AU - Fujimoto, Nobukazu

PY - 1996/10

Y1 - 1996/10

N2 - Serum soluble cytokeratin 19 fragment (CYFRA) levels were measured in 251 patients with lung cancer and 139 patients with benign lung diseases to determine the clinical usefulness of CYFRA level determination in the diagnosis and monitoring of lung cancer. Serum levels of CYFRA were measured by a 2-step sandwich ELISA method. When the cut-off value was defined as 3.5 ng/ml, which was associated with a specificity of 95% for benign lung diseases, CYFRA had a high sensitivity (53%) in all patients with lung cancer. Both the serum level of CYFRA and its sensitivity increased significantly with the increase in clinical stage. A comparison of areas under receiver operating characteristic curves showed that CYFRA had the most power of discrimination in the diagnosis of lung cancer among markers including carcinoembryonic antigen, squamous cell carcinoma antigen, carbohydrate antigen 19-9, and neuron-specific enolase. A good correlation was found between serial changes in serum CYFRA levels during therapy and clinical responses for 18 patients who underwent chemotherapy and/or radiotherapy. Our findings suggest that CYFRA may be a marker of choice for screening and monitoring of lung cancer, particularly squamous cell carcinoma.

AB - Serum soluble cytokeratin 19 fragment (CYFRA) levels were measured in 251 patients with lung cancer and 139 patients with benign lung diseases to determine the clinical usefulness of CYFRA level determination in the diagnosis and monitoring of lung cancer. Serum levels of CYFRA were measured by a 2-step sandwich ELISA method. When the cut-off value was defined as 3.5 ng/ml, which was associated with a specificity of 95% for benign lung diseases, CYFRA had a high sensitivity (53%) in all patients with lung cancer. Both the serum level of CYFRA and its sensitivity increased significantly with the increase in clinical stage. A comparison of areas under receiver operating characteristic curves showed that CYFRA had the most power of discrimination in the diagnosis of lung cancer among markers including carcinoembryonic antigen, squamous cell carcinoma antigen, carbohydrate antigen 19-9, and neuron-specific enolase. A good correlation was found between serial changes in serum CYFRA levels during therapy and clinical responses for 18 patients who underwent chemotherapy and/or radiotherapy. Our findings suggest that CYFRA may be a marker of choice for screening and monitoring of lung cancer, particularly squamous cell carcinoma.

KW - Carbohydrate antigen 19-9

KW - Carcinoembryonic antigen

KW - Neuron-specific enolase

KW - Non-small cell lung cancer

KW - Squamous cell carcinoma

KW - Squamous cell carcinoma antigen

UR - http://www.scopus.com/inward/record.url?scp=0030253443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030253443&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 764

EP - 771

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 10

ER -